Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting

The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed radically in recent years. Androgen deprivation therapy (ADT) alone was for decades the standard of care for treating mHSPC. This changed when studies showed that the addition of docetaxel chemotherapy or abi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kenrick, Smith, Shievon, Shamash, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683690/
https://www.ncbi.nlm.nih.gov/pubmed/32700045
http://dx.doi.org/10.1007/s40487-020-00119-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683690/
https://www.ncbi.nlm.nih.gov/pubmed/32700045
http://dx.doi.org/10.1007/s40487-020-00119-z

Ejemplares similares